[HTML][HTML] Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …
What is the pipeline for future medications for obesity?
E Melson, U Ashraf, D Papamargaritis… - International Journal of …, 2024 - nature.com
Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …
and mortality. Our better understanding of the weight regulation mechanisms and the role of …
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
M Tschöp, R Nogueiras, B Ahrén - Diabetologia, 2023 - Springer
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …
Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials
Aim To perform a meta‐analysis to quantify the effect of tirzepatide on blood pressure and
lipids. Methods PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and …
lipids. Methods PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and …
Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
S Chiappini, R Vickers-Smith, D Harris… - Pharmaceuticals, 2023 - mdpi.com
Recent media reports commented about a possible issue of the misuse of antidiabetics
related to molecules promoted as a weight-loss treatment in non-obese people. We …
related to molecules promoted as a weight-loss treatment in non-obese people. We …
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Q Zeng, J Xu, X Mu, Y Shi, H Fan, S Li - Frontiers in Endocrinology, 2023 - frontiersin.org
Purpose A systematic review and meta-analysis was conducted to synthesize the available
data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and …
data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and …
[HTML][HTML] Future therapies for obesity
Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric
surgery can lead to sustained long-term weight loss (WL) and improvement in multiple …
surgery can lead to sustained long-term weight loss (WL) and improvement in multiple …
Novel dual incretin receptor agonists in the spectrum of metabolic diseases with a focus on tirzepatide: real game-changers or great expectations? A narrative review
AL Liarakos, C Koliaki - Biomedicines, 2023 - mdpi.com
The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-
alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for …
alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for …
[HTML][HTML] Perspectives on weight control in diabetes–Tirzepatide
TT Várkonyi, A Pósa, N Pávó, I Pavo - Diabetes Research and Clinical …, 2023 - Elsevier
Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-
like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 RA) improves glycemic control. Besides …
like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 RA) improves glycemic control. Besides …
[HTML][HTML] GLP-1R mediates idebenone-reduced blood glucose in mice
X Zhao, Q Zeng, S Yu, X Zhu, B Hu, L Deng… - Biomedicine & …, 2024 - Elsevier
Abstract GLP-1 receptor agonists (GLP-1RAs) are an innovative class of drugs with
significant therapeutic value for type 2 diabetes mellitus (T2DM). The GLP-1RAs currently …
significant therapeutic value for type 2 diabetes mellitus (T2DM). The GLP-1RAs currently …